Quick Answer
NovoCure Ltd reported Total Revenue of $655.35 million for fiscal year 2025.
NovoCure Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $655.35M +8.3% |
$605.22M +18.8% |
$509.34M -5.3% |
$537.84M +0.5% |
$535.03M +8.2% |
$494.37M +40.7% |
| Net Income | -$136.23M +19.2% |
-$168.63M +18.6% |
-$207.04M -123.7% |
-$92.53M -58.6% |
-$58.35M -394.6% |
$19.81M +374.0% |
| Diluted EPS | -$1.22 +21.8% |
-$1.56 +20.0% |
-$1.95 -121.6% |
-$0.88 -57.1% |
-$0.56 -411.1% |
$0.18 +357.1% |
| Total Assets | $804.33M -35.2% |
$1.24B +8.3% |
$1.15B -3.8% |
$1.19B +4.6% |
$1.14B +8.3% |
$1.05B +119.4% |
| Cash and Equivalents | $93.55M -42.9% |
$163.77M -32.0% |
$240.82M +108.8% |
$115.33M -44.8% |
$208.80M -11.0% |
$234.67M +32.3% |
| Long-Term Debt | — | — | $568.82M +0.6% |
$565.51M +0.6% |
$562.22M +30.8% |
$429.90M +187.7% |
| Stockholders Equity | $340.47M -5.5% |
$360.18M -0.6% |
$362.50M -17.8% |
$441.17M +7.5% |
$410.49M -13.9% |
$476.53M +118.8% |
| R&D Expense | $224.54M +7.1% |
$209.65M -6.0% |
$223.06M +8.2% |
$206.09M +2.4% |
$201.30M +52.5% |
$132.01M +67.1% |
| Operating Income | -$153.80M +9.8% |
-$170.50M +26.8% |
-$232.87M -160.1% |
-$89.52M -101.9% |
-$44.33M -245.8% |
$30.40M +3426.1% |
| Gross Profit | $488.47M +4.4% |
$468.04M +22.8% |
$381.06M -9.9% |
$422.97M +0.7% |
$420.15M +8.3% |
$387.87M +47.6% |
| Shares Outstanding | 112.49M +3.7% |
108.52M +1.3% |
107.08M +1.9% |
105.05M +1.0% |
103.97M +1.6% |
102.33M +2.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $167.20M | +7.8% | +5.3% |
| Net Income | September 30, 2025 | -$37.27M | -21.9% | +7.1% |
| Diluted EPS | September 30, 2025 | -$0.33 | -17.9% | +8.3% |
| Total Assets | September 30, 2025 | $1.36B | +11.4% | +9.3% |
| Cash and Equivalents | September 30, 2025 | $342.12M | +84.5% | +128.7% |
| Long-Term Debt | March 31, 2024 | $569.65M | +0.6% | +0.1% |
| Stockholders Equity | September 30, 2025 | $341.33M | -5.4% | -2.3% |
| R&D Expense | September 30, 2025 | $54.03M | +4.1% | -3.2% |
| Operating Income | September 30, 2025 | -$36.02M | -12.2% | +8.9% |
| Gross Profit | September 30, 2025 | $122.47M | +2.3% | +4.4% |
| Shares Outstanding | September 30, 2025 | 111.98M | +3.6% | +0.2% |
- NovoCure Ltd reported Total Revenue of $655.35 million for fiscal year 2025.
- NovoCure Ltd showed an increase of +8.3% in Total Revenue compared to the prior fiscal year.
- NovoCure Ltd reported Net Income of -$136.23 million for fiscal year 2025.
- NovoCure Ltd showed an increase of +19.2% in Net Income compared to the prior fiscal year.
- NovoCure Ltd reported Diluted EPS of $1.22 per share (loss) for fiscal year 2025.
- NovoCure Ltd showed an increase of +21.8% in Diluted EPS compared to the prior fiscal year.
- NovoCure Ltd reported Total Assets of $804.33 million for fiscal year 2025.
- NovoCure Ltd showed a decrease of -35.2% in Total Assets compared to the prior fiscal year.
- NovoCure Ltd reported Cash and Equivalents of $93.55 million for fiscal year 2025.
- NovoCure Ltd showed a decrease of -42.9% in Cash and Equivalents compared to the prior fiscal year.
- NovoCure Ltd reported Long-Term Debt of $568.82 million for fiscal year 2023.
- NovoCure Ltd showed an increase of +0.6% in Long-Term Debt compared to the prior fiscal year.
- NovoCure Ltd reported Stockholders Equity of $340.47 million for fiscal year 2025.
- NovoCure Ltd showed a decrease of -5.5% in Stockholders Equity compared to the prior fiscal year.
- NovoCure Ltd reported R&D Expense of $224.54 million for fiscal year 2025.
- NovoCure Ltd showed an increase of +7.1% in R&D Expense compared to the prior fiscal year.
- NovoCure Ltd reported Operating Income of -$153.80 million for fiscal year 2025.
- NovoCure Ltd showed an increase of +9.8% in Operating Income compared to the prior fiscal year.
- NovoCure Ltd reported Gross Profit of $488.47 million for fiscal year 2025.
- NovoCure Ltd showed an increase of +4.4% in Gross Profit compared to the prior fiscal year.
- NovoCure Ltd reported Shares Outstanding of 112.49 million shares for fiscal year 2025.
- NovoCure Ltd showed an increase of +3.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: